These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22137084)

  • 1. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure.
    Postmus D; Pari AA; Jaarsma T; Luttik ML; van Veldhuisen DJ; Hillege HL; Buskens E
    Am Heart J; 2011 Dec; 162(6):1096-104. PubMed ID: 22137084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH).
    Jaarsma T; van der Wal MH; Lesman-Leegte I; Luttik ML; Hogenhuis J; Veeger NJ; Sanderman R; Hoes AW; van Gilst WH; Lok DJ; Dunselman PH; Tijssen JG; Hillege HL; van Veldhuisen DJ;
    Arch Intern Med; 2008 Feb; 168(3):316-24. PubMed ID: 18268174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of telephonic disease management in heart failure.
    Smith B; Hughes-Cromwick PF; Forkner E; Galbreath AD
    Am J Manag Care; 2008 Feb; 14(2):106-15. PubMed ID: 18269306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure.
    Del Sindaco D; Pulignano G; Minardi G; Apostoli A; Guerrieri L; Rotoloni M; Petri G; Fabrizi L; Caroselli A; Venusti R; Chiantera A; Giulivi A; Giovannini E; Leggio F
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):324-9. PubMed ID: 17443097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
    Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
    Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
    Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care).
    Maru S; Byrnes J; Carrington MJ; Chan YK; Thompson DR; Stewart S; Scuffham PA;
    Int J Cardiol; 2015 Dec; 201():368-75. PubMed ID: 26310979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure.
    Galbreath AD; Krasuski RA; Smith B; Stajduhar KC; Kwan MD; Ellis R; Freeman GL
    Circulation; 2004 Dec; 110(23):3518-26. PubMed ID: 15531765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure disease management programs: a cost-effectiveness analysis.
    Chan DC; Heidenreich PA; Weinstein MC; Fonarow GC
    Am Heart J; 2008 Feb; 155(2):332-8. PubMed ID: 18215605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation.
    Hendriks J; Tomini F; van Asselt T; Crijns H; Vrijhoef H
    Europace; 2013 Aug; 15(8):1128-35. PubMed ID: 23515338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.
    Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of a nurse-based heart failure management program on hospitalization rate, functional status, quality of life, and medical costs].
    Chinaglia A; Gaschino G; Asteggiano R; Titta G; Gullstrand R; Bobbio M; Trinchero R
    Ital Heart J Suppl; 2002 May; 3(5):532-8. PubMed ID: 12064192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of a disease management program for patients with asthma.
    Steuten L; Palmer S; Vrijhoef B; van Merode F; Spreeuwenberg C; Severens H
    Int J Technol Assess Health Care; 2007; 23(2):184-91. PubMed ID: 17493304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.